Silo Pharma (SILO) said Wednesday the US Patent and Trademark Office issued a notification for its "Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females" application.
The patent reinforces protection for its lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder, the company said.
"This new patent further supports our collaborative research with Columbia University and expands coverage for SPC-15," said Chief Executive Officer Eric Weisblum.
Price: 1.36, Change: -0.03, Percent Change: -2.16
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.